DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1141-1143

  Syampurnawati, Meilani ^a,b   Tatsumi, Eiji ^a   Ardianto, Bambang ^a   Takenokuchi, Mariko ^a   Nakamachi, Yuji ^a   Kawano, Seiji ^a   Kumagai, Shun ichi ^a   Saigo, Katsuyasu ^c   Matsui, Toshimitsu ^d   Takahashi, Takayuki ^e   Nagai, Ken ichi ^f   Gunadi, ^a   Nishio, Hisahide ^a   Yabe, Hiroki ^g   Kondo, Shin ichi ^h   Hayashi, Yoshitake ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KOBE UNIVERSITY HOSPITAL   (Japan)

^e KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^f INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^g Ako Municipal Hospital   (Japan)

^h National Kakogawa Hospital   (Japan)

Author keywords

FLT3 mutation; HLA DR negative AML; NPM1 mutation

Indexed keywords

CD135 ANTIGEN; HLA DR ANTIGEN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CLINICAL FEATURE; GENE MUTATION; HUMAN; KARYOTYPE; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL;

BASE SEQUENCE; DNA, COMPLEMENTARY; HLA-DR ANTIGENS; HUMANS; LEUKEMIA, MYELOID, ACUTE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 41949127653     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.017     Document Type: Article

References (14)

1. Grisendi S., Mecucci C., Falini B., and Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 6 7 (2006) 493-505
2. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 3 (2005) 254-266
3. Falini B., Bolli N., Shan J., Martelli M.P., Liso A., Pucciarini A., et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of Nucleophosmin leukemic mutants in NPMc+ AML. Blood 107 11 (2006) 4514-4523
4. Syampurnawati M., Tatsumi E., Furuta K., Takenokuchi M., Nakamachi Y., Kawano S., et al. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. Leuk Res 31 7 (2007) 921-929
5. Verhaak R.G., Goudswaard C.S., van Putten W., Bijl M.A., Sanders M.A., Hugens W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106 12 (2005) 3747-3754
6. Roti G., Rosati R., Bonasso R., Gorello P., Diverio D., Martelli M.F., et al. Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn 8 2 (2006) 254-259
7. Schnittger S., Schoch C., Kern W., Mecucci C., Tschulik C., Martelli M.F., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106 12 (2005) 3733-3739
8. Thiede C., Creutzig E., Illmer T., Schaich M., Heise V., Ehninger G., et al. Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Leukemia 20 10 (2006) 1897-1899
9. Alcalay M., Tiacci E., Bergomas R., Bigerna B., Venturini E., Minardi S.P., et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 106 3 (2005) 899-902
10. Chou W.C., Tang J.L., Lin L.I., Yao M., Tsay W., Chen C.Y., et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 66 6 (2006) 3310-3316
11. Chen W., Rassidakis G.Z., Li J., Routbort M., Jones D., Kantarjian H., et al. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood 108 5 (2006) 1783-1784
12. Kussick S.J., Stirewalt D.L., Yi H.S., Sheets K.M., Pogosova-Agadjanyan E., Braswell S., et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia 18 10 (2004) 1591-1598
13. Matsunaga K., Yano M., Joukei Y., Kikuma C., Okazaki Y., Masuda Y., et al. FLT3 ITD (internal tandem duplication) and morphological evaluation in 2 cases of DR-negative acute myeloblastic leukemia (AML) (M2) having cells with conspicuous granules. J Jpn Lab Hematol Soc 7 2 (2006) 264-268 (Abs in English)
14. Wilson C.S., Davidson G.S., Martin S.B., Andries E., Potter J., Harvey R., et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108 2 (2006) 685-696